Avalo Therapeutics enters $75M ATM equity offering with TD Cowen, terminates prior Oppenheimer facility

Avalo Therapeutics, Inc.

Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.
Commission to TD Cowen is up to 3% of gross proceeds from sales.
Terminated prior ATM agreement with Oppenheimer (originally $50M) effective June 4, 2025; no penalties.
Offering is made under existing effective S-3 registration statement (File No. 333-271225).

item 1.01item 1.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.